more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? the impact of gender in the RITA 3 trial. Eur Heart J 2004; 25: 1641–50. RITA 3: increased mortality with an invasive strategy in women.
2 133. O’Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2008; 300: 71–80.
3 134. Mega JL, Hochman JS, Scirica BM, et al. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). Circulation 2010; 121: 1809–17.
4 135. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med 1999; 341: 226–32.
Elderly and ACS
1 136. Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141: 186–95.
2 137. Tegn N, Abdelnoor M, Aaberge L, et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial. Lancet 2016; 387: 1057–65.
CKD
1 138. Fox KA, Antman EM, Montalescot G, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49: 2249–55.
2 139. Januzzi JL, Cannon CP, DiBattiste PM; TACTICS-TIMI 18 Investigators. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (the TACTICS-TIMI 18 Trial). Am J Cardiol 90 2002: 1246–9.
3 140. Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011; 4: 1002–8.
Bleeding
1 141. Mehran R, Pocock S, Nikolsky E, et al. Impact of bleeding on mortality after percutaneous coronary intervention. Results from a patient pooled analysis of the REPLACE-2, ACUITY, and HORIZONS-AMI trials. J Am Coll Cardiol 2011; 4: 654–64.
2 142. Manoukian SV, Feit F, Mehran R. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 2007; 47; 1362–8.
Transfusion in ACS
1 143. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009; 53: 2019–27.
2 144. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555–62. +from Crusade registry: Alexander KP, Chen AY, Wang TY, et al. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J 2008; 155: 1047–53.
3 145. A randomized trial of liberal vs. restrictive red blood cell transfusion strategies in patients with acute myocardial infarction and anemia. Presented by Steg PG, at ESC 2020.
4 146. Steg PG, Hubert K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854–64.
5 147. Hanna EB, Alexander KP, Chen AY, et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction undergoing an invasive strategy according to hemoglobin levels. Am J Cardiol 2013; 111(8): 1099–103.
6 148. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969–74. WARIS 2.
7 149. Van ES, Jonker JJ, Verheugt FWA, et al. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study). Lancet 2002; 360: 109–11.
GI bleed
1 150. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52; 1502–17.
Antiplatelet and anticoagulant therapies in ACS
1 151. Mehta SR, Bassand JP, Chrolavicius S, et al. CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930–42.
2 152. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33.
3 153. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52: 1693–701.
4 154. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY trial. J Am Coll Cardiol 2009; 53: 1965–1972.
5 155. Firanescu CE, Martens EJ, Schönberger JP, et al. Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel: a prospective randomised controlled study. Eur J Cardiothorac Surg 2009; 36: 856–62.
6 156. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
7 157. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57. PLATO trial.
8 158. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008; 118: 1626–36.
9 159. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–31.
10 160. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297–309.
11 161. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303–13.
12 162 Kastrati A, Mehilli J, Neumann FJ, et al. ISAR-REACT 2 Trial Investigators Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 2006: 1531–8.
13 163. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI study. J Am Coll Cardiol 2012; 59: 2159–64. +Also, GRAVITAS trial: Price MJ, Berger PB, Teirstein PS, et al. Standard- vs